TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02614365

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Cardiovascular fitness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretch exercise
Description: Muscle stretch
Study: NCT00823823

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bivalved cast
Description: Circumferential cast will be applied following closed reduction and then bivalved using a cast saw

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Circumferential cast
Description: Circumferential cast will be applied following closed reduction
Study: NCT00066768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suramin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03044938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol
Description: Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
Study: NCT04107415

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: yoga
Description: A total of 12 yoga sessions, 2 sessions a week for 6 weeks, was applied to the patients in the experimental group.
Study: NCT00319280

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)
Description: Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)
Description: Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)
Description: Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
Study: NCT03016208

Intervention type: DRUG
Intervention: Misoprostol vaginal insert

Intervention type: DRUG
Intervention: Misoprostol vaginal insert
Study: NCT00050648

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: 1mg/kg medication every other week on the odd week (week 1-13).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: 2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine and Daclizumab
Description: 1mg/kg plus low dose cyclosporine (2 mg/kg/day)
Study: NCT01039077

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastric banding
Description: Laparoscopic gastric banding for the treatment of morbid obesity.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic gastric banding
Description: Laparoscopic gastric banding for the treatment of morbid obesity.
Study: NCT01186796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:~(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.~\*\*Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit).
Study: NCT04602169

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Description: PV re-isolation will be conducted according to the CLOSE-protocol. Point-by-point radiofrequency (RF) delivery will be performed aiming for a contiguous circle enclosing all PVs. RF will be delivered in a power-controlled mode (without ramping) using 35-40 Watt. The irrigation rate will be set at 30 ml/min. RF will be delivered until an ablation index (AI) of ≥400 is reached at the posterior wall and ≥550 at the anterior wall. In case of dislocation, a new RF application reaching the AI target will be applied. Maximal intertag distance between two neighboring lesions is 6 mm. In case of intra-esophageal temperature (T°) rise \>38.5°C during posterior LA wall ablation, RF delivery will stopped at an AI of 300. In the absence of first pass isolation, touch-up ablation was applied until PVI. In case of reconnection during the waiting time or during the adenosine test, the site of reconnection will be located and treated with touch-up ablation until adenosine proof PVI is reached.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI + SVC
Description: Patients in this group receive PVI according to the CLOSE protocol. In addition, they will receive an SVC isolation. The circular mapping catheter will be introduced in the superior vena cava to determine baseline electrical activity and to confirm definite entrance and exit block after ablation. Ablation will be performed proximally to the SVC/right atrial junction with the contact force-catheter using circular point-by-point radiofrequency delivery with a power setting of 35W, targeting an AI ≥400. High output (25 mA) pacing will be applied before each RF application to check for phrenic nerve stimulation. In areas of phrenic nerve capture ablation will be avoided even in case of incomplete isolation.
Study: NCT03969849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713-5714-5715
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713-5714-5715
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713-5714-5715
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713-5714-5715
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN5713-5714-5715
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo
Description: Part A: Cohort 1 - 3: Single sequential ascending subcutaneous (SC) dose Part A: Cohort 4: Single intravenous (IV) dose Part B: Single SC dose
Study: NCT02171962

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Zilver® PTX® Drug-Eluting Peripheral Stent
Description: Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
Study: NCT02806089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Handheld dynamometer
Description: Evaluation of muscle strength

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Creatinine index
Description: Evaluation of muscle mass using plasma creatinine level
Study: NCT03290066

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: kinesiotape
Description: For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
Study: NCT02806089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical bioimpedance analysis
Description: Evaluation of lean body mass

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Voorrips score questionnaire
Description: Evaluation of physical activity

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inflammatory and nutritional status
Description: Evaluation of C reactive protein and albumin
Study: NCT04429165

Intervention type: OTHER
Intervention: collection of Patient Reported Outcome (PRO) data
Description: collection of Patient Reported Outcome (PRO) data by questionnaires

Intervention type: OTHER
Intervention: collection of Patient Reported Outcome (PRO) data
Description: collection of Patient Reported Outcome (PRO) data by questionnaires

Intervention type: OTHER
Intervention: collection of anthropometric and clinical functional data
Description: collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity

Intervention type: OTHER
Intervention: collection of anthropometric and clinical functional data
Description: collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity

Intervention type: OTHER
Intervention: gait analysis
Description: gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded

Intervention type: OTHER
Intervention: gait analysis
Description: gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded
Study: NCT02613884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment
Study: NCT02355249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIE
Description: Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OE
Description: Patients will be treated with traditional three incisions esophagectomy.
Study: NCT03725579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivicane hydrochloride
Description: Pain will be assessed during access cavity preparation and instrumentation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepivicane hydrochloride
Description: Pain will be assessed during access cavity preparation and instrumentation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: articane hydrochloride
Description: Pain will be assessed during access cavity preparation and instrumentation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articane hydrochloride
Description: Pain will be assessed during access cavity preparation and instrumentation
Study: NCT04200235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride nasal spray
Description: In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride nasal spray
Description: In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride nasal spray blank preparation.
Description: In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride nasal spray blank preparation.
Description: In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Study: NCT01966614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: Single intraprostatic bilateral injection at a dose of 0.6 µg/g
Study: NCT01924338

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser scan
Description: A near-infrared laser scan of the subject's forehead is acquired

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser scan
Description: A near-infrared laser scan of the subject's forehead is acquired

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser scan
Description: A near-infrared laser scan of the subject's forehead is acquired

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser scan
Description: A near-infrared laser scan of the subject's forehead is acquired

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental cast creation
Description: A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental cast creation
Description: A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental cast creation
Description: A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental cast creation
Description: A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
Study: NCT03886896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine infusion during surgery
Study: NCT05784493

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study group
Description: Washing by heated saline group
Study: NCT01966614

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intraprostatic bilateral injection of vehicle only
Study: NCT02429726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAdp53
Description: Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered by intra chest cavity infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAdp53 plus cisplatin
Description: Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
Study: NCT02224313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral estradiol 1.0 mg
Description: one tablet of oral estradiol 1.0 mg once a day for 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral progesterone 100 mg
Description: one tablet of oral progesterone 100 mg once a day for 14 days
Study: NCT00770770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.2 µg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.5 µg/day
Study: NCT01439542

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Description: 12 months (2x6 month depot) of androgen suppression with LHRH agonist
Study: NCT03568045

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard light
Description: usual care

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10,000 lux bright light, 4 hours
Description: Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10,000 lux bright light, 8 hours
Description: Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
Study: NCT02700412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
Study: NCT01440270

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Erbitux-based chemotherapy
Description: Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy
Study: NCT02484976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Behavioral Treatment
Description: Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
Study: NCT02685423

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binocular deprivation 10 days
Description: Research participants will be asked to live 10 days in an experimentally-controlled dark environment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vision training
Description: Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vision training
Description: Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.